我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

奥美沙坦对大鼠移植静脉内膜重构过程中整合素β-3/FAK信号蛋白表达的影响

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2010年第2期
页码:
164-167
栏目:
基础研究
出版日期:
2010-03-04

文章信息/Info

Title:
Expression of integrin β-3/focal adhesion kinase on intimal remodeling of rat vein graft: modulation by olmesartan
作者:
肖平喜1; 田乃亮1; 葛震1; 张娟1; 裴兆辉2; 王礼春2; 马虹2
1.南京医科大学附属南京第一医院心内科，江苏 南京 210006；2.中山大学附属第一医院心内科，广东 广州 510080
Author(s):
XIAO Ping-xi1;  TIAN Nai-liang1;  GE Zhen1;  ZHANG Juan1;  PEI Zhao-hui2;  WANG Li-chun2;  MA Hong2
1.Department of Cardiology, Nanjing First Hospital Affiliated Nanjing Medical University, Nanjing 210006, Jiangsu, China; 2.First Affiliated Hospital, SUN YAT-sen University, Guangzhou 510080, Guangdong, China
关键词:
奥美沙坦; 重构; 黏着斑激酶
Keywords:
olmesartan;  remodeling;  focal adhesion kinase
分类号:
R972
DOI:
-
文献标识码:
A
摘要:
目的: 观察奥美沙坦对大鼠移植静脉内膜重构过程中整合素β-3（integrinβ-3）黏着斑激酶（focal adhesion kinase，FAK）表达的影响。方法: 建立大鼠移植静脉桥模型，将36只雄性SD大鼠被随机分成模型对照组、奥美沙坦组及生理盐水对照组，每组12只。取移植静脉切片、HE染色观察各组血管壁内膜的厚度。采用免疫组化染色法观察各组血管平滑肌细胞（SMC）增殖核抗原（PCNA）的表达。采用Western blot法检测整合素β-3和FAK的表达。结果: 与模型对照组相比，奥美沙坦组内膜的厚度明显减轻（P<0.05）；PCNA和FAK的表达明显降低（P<0.05）。生理盐水对照组与模型对照组相比，内膜的厚度无明显减轻；PCNA和FAK的表达无明显改变。结论: 大鼠移植静脉内膜重构过程中，伴随整合素β-3/FAK信号蛋白的表达，奥美沙坦可抑制大鼠移植静脉内膜重构，此作用可能与下调FAK信号蛋白的表达有关。
Abstract:
AIM: To observe the expression of focal adhesion kinase in rat’s autologous vein graft and its modulating effect by olmesartan (a specific type 1 angiotensin II receptor antagonist). METHODS: Autologous external jugular veins were grafted to common carotid arteries in 36 male Wistar rats. After surgery, rats were randomly assigned to three groups (12 rats in each): model control group, olmesartan group and physiological saline group. The intimal thickness in vein grafts was quantitated in H/E-stained segments. Integrin β-3 and focal adhesion kinase expression levels were assessed by Western blotting, and proliferating cell nuclear antigen (PCNA) was measured by immunohistochemistry. RESULTS: Neointimal hyperplasia was observed in model control group characterized by significant intimal thickening. The expressions of integrin β-3, FAK and PCNA were positive in model control group. Compared with that in model control group, the intimal thickness was significantly attenuated in olmesartan group (P<0.05) and the expressions of FAK and PCNA significantly reduced (P<0.05). CONCLUSION: FAK is involved in the restenosis of vein graft in rats. Olmesartan attenuates the restenosis of rat vein graft, possibly through its downregulating effect on FAK.

参考文献/References

［1］ 兰锡纯，冯卓荣. 心脏血管外科学［M］. 北京: 人民卫生出版社, 2002:859-962.

［2］ Yoshida Y, Mitsumata M, Ling G, et al. Migration of medial smooth muscle cells to the intima after balloon injury［J］. Ann N Y Acad Sci, 1997, 8（11）:459-470.

［3］ 温进坤,韩梅,程云会，等. 整合素β-3-粘着斑激酶信号途径的活化参与大鼠血管新生内膜的形成［J］. 中国病理生理杂志, 2006, 22(10):1922-1925.

［4］ Yau JM, Alexander JH, Hafley G, et al. Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of ex-vivo Vein graft ENgineering via Transfection［J］. Am J Cardiol, 2008, 102(5):546-551.

［5］ Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system［J］. Am J Physiol Cell Physiol, 2007, 292(1):C82-C97.

［6］ Furubayashi K, Takai S, Jin D, et al. The significance of chymase in the progression of abdominal aortic aneurysms in dogs［J］. Hypertens Res, 2007, 30(4):349-357.

［7］ Govindarajan G, Eble DM, Lucchesi PA, et al. Focal adhesion kinase is involved in angiotensin II-mediated protein synthesis in cultured vascular smooth muscle cells［J］. Circulation Res, 2000, 87(8):710-716.

［8］ Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies［J］. Fundam Clin Pharmacol, 2007, 21(2):181-190.

［9］ Mizuno M, SadaT, Ikeda M, et al. Pharmacology of CS-866, a novel nonpeptide angiotensinⅡ receptor antagonist［J］. Eur J Pharmacol, 1995, 285(2):181-188.

［10］Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin Ⅱ type AT1receptor antagonist［J］. J Hypertens Suppl, 2001, 19(1):S3-S14.

［11］Warner GT, Jarvis B. Olmesartan medoxomil［J］. Drugs, 2002, 62(9):1345-1353.

［12］Li S, Wang X, Qiu J, et al. Angiotensin II stimulates endothelial integrin beta3 expression via nuclear factor-kappaB activation［J］. Exp Aging Res, 2006, 32(1):47-60.

［13］Li X, Lee JW, Graves LM, et al. Angiotensin II stimulates ERK via two pathways in epithet- lial cells: protein kinase C suppresses a G-protein coupled receptor-EGF receptor transactivation pathway［J］. EMBO J, 1998, 17(9):2574-2583.

备注/Memo

备注/Memo:
收稿日期：2009-3-29.通讯作者:裴兆辉,副主任医师,主要从事心血管临床与基础研究Email:leak123@126.com作者简介:肖平喜,医师,博士Email:sysu-xiao@163.com
更新日期/Last Update: 2010-03-05